Likewise, systemic targeting of TIM-3, an immune checkpoint that functions to suppress T cell responses, has been shown to more potently suppress tumour growth and improve the anti-tumour efficacy of an anti-PD1 scFV HSV OV [77]. This evidence concerns the gene HAVCR2 and neoplasm.